Showing 2431-2440 of 6036 results for "".
- CMS Proposes to Eliminate Medicare Certification Requirements for Comprehensive H&Ps and Transfer Agreements with Hospitalshttps://modernod.com/news/cms-proposes-to-eliminate-medicare-certification-requirements-for-comprehensive-hps-and-transfer-agreements-with-hospitals/2479844/The Outpatient Ophthalmic Surgery Society (OOSS) issued the following statement in response to recent changes in the Centers for Medicare & Medicaid Services (CMS) Medicare payment policy concerning ambulatory surgery centers (ASCs). “Last week, CMS proposed reducing, modifying,
- Positive PEACHTREE Data to be Highlighted at Euretina 2018https://modernod.com/news/positive-peachtree-data-to-be-highlighted-at-euretina-2018/2479871/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann, MD, Uveitis Specialist at Maccabi Health Services, Tel Aviv, Israel and co-Chair of
- SightMD, 24-Location Ophthalmology Group, and Chicago Pacific Founders Set Partnershiphttps://modernod.com/news/sightmd-24-location-ophthalmology-group-and-chicago-pacific-founders-set-partnership/2479899/SightMD, a provider of eyecare services through 24 locations, and Chicago Pacific Founders Fund LP, a health care investment fund, announced that they are entering into a partnership to expand SightMD’s patient-centric care model to patients, providers, and payers across the New York, New Jersey
- EyeSouth Expands into South Florida Through Affiliation with Florida Eye Microsurgical Institutehttps://modernod.com/news/eyesouth-expands-into-south-florida-through-affiliation-with-florida-eye-microsurgical-institute/2479907/EyeSouth Partners has announced that it has completed a strategic partnership with Florida Eye Microsurgical Institute and Boynton Beach ASC, expanding its presence into the South Florida region. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a l
- EyeQue Expands Vision Monitoring for Consumers, Adding Color and Contrast Sensitivity Tests to Insight Vision Screenerhttps://modernod.com/news/eyeque-expands-vision-monitoring-for-consumers-adding-color-and-contrast-sensitivity-tests-to-insight-vision-screener/2479923/EyeQue announced the addition of two new vision tests to its EyeQue Insight vision screener—color vision and contrast sensitivity testing. The EyeQue Insight combines a binocular viewer, mobile application and cloud-based service to create the world’s first smartphone-powered vision screener, acc
- EyeSouth Announces Strategic Partnership with South Georgia/North Florida Eye Partnershttps://modernod.com/news/eyesouth-announces-strategic-partnership-with-south-georgia-north-florida-eye-partners/2480107/EyeSouth Partners has completed a strategic partnership with South Georgia/North Florida Eye Partners, and Cataract and Laser Surgery Center of South Georgia, expanding its presence into the South Georgia and North Florida regions. EyeSouth is an eye care-focused physician services organization f
- IDOC Launches Easyvision Private Label Contact Lens Portfolio for Independent Optometristshttps://modernod.com/news/idoc-launches-easyvision-private-label-contact-lens-portfolio-for-independent-optometrists/2486489/Key Takeaways easyvision is a new private label daily disposable contact lens portfolio from IDOC, manufactured by CooperVision
- SignaBlok Receives Orphan Drug Designation From FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurityhttps://modernod.com/news/signablok-receives-orphan-drug-designation-from-fda-for-a-first-in-class-trem-1-peptide-inhibitor-for-the-treatment-of-retinopathy-of-prematurity/2486398/Key Takeaways The FDA granted Orphan Drug Designation to SignaBlok’s triggering receptor expressed on myeloid cells 1 peptide inhibitor for treating retinopathy of prematurity According to the company, the designation highlights the therapy’s potential as a
- TP-03 Now Approved in China for the Treatment of Demodex Blepharitishttps://modernod.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486355/Key Takeaways TP-03 (XDEMVY) has been approved in China by the NMPA for treating Demodex blepharitis, marking a major expansion beyond th
- Study Finds GLP-1 Drugs Linked to Lower Risk of Legal Blindness in Type 2 Diabeteshttps://modernod.com/news/study-finds-glp-1-drugs-linked-to-lower-risk-of-legal-blindness-in-type-2-diabetes/2486332/A large real-world study suggests that widely used GLP-1 receptor agonists—commonly prescribed for type 2 diabetes and weight management—may significantly reduce the risk of legal blindness in high-risk patients. The research,